Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 5)
Meds Like Ozempic Are Causing Folks to Waste More Food
FRIDAY, Nov. 22, 2024 – America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy,...
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
FRIDAY, Nov. 22, 2024 – More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the ...
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
FRIDAY, Nov. 22, 2024 – Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Than Half of U.S. Adults Could Be Candidates for Ozempic
TUESDAY, Nov. 19, 2024 – More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds. Sold as Ozempic for...
Diabetes Meds Metformin, GLP-1s Can Also Curb Asthma
MONDAY, Nov. 18, 2024 – Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows. The two drugs are metformin, one of...
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
THURSDAY, Nov. 14, 2024 – For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE),...
Ozempic Could Help Curb Alcoholism
WEDNESDAY, Nov. 13, 2024 – The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
MONDAY, Nov. 11, 2024 – The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes m...
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
THURSDAY, Nov. 7, 2024 – The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
TUESDAY, Nov. 5, 2024 – Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover t...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2